/

Halozyme Therapeutics, Inc.

HALO US

HALO USHalozyme Therapeutics, Inc.

United States Composite

39.82

USD

+0.52

(+1.32%)

2.10EPS Dil.

18.66P/E

5.05BMarket Cap

Next Earnings

May 7

Held by Insiders

1.07%

Held by Institutions

100.11%

Short % of Float

6.37%

YTD Yield

19.48%

3Y Yield

-21.45%

5Y Yield

126.64%

Capital Structure

FRC

•

in mil. unless spec.

Jun'23

Sep'23

Dec'23

ST Debt

- -

LT Borrowings

1,496

1,498

1,499

LT Finance Leases

- -

Preferred Equity and Hybrid Capital

- -

Shares Outstanding

132

127

Market Capitalization

4,756

5,045

4,685

Working Capital

FRC

•

in mil. unless spec.

Jun'23

Sep'23

Dec'23

Total Current Assets

766

879

746

Cash, Cash Equivalents & STI

348

483

336

Accounts Receivable, Net

228

220

233

Inventories

132

129

128

Total Current Liabilities

116

115

112

Payables & Accruals

116

115

112

ST Debt

- -

Deferred Revenue

- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years

5 years

1 year

Sales/Revenue/Turnover

39.44%

41.11%

25.61%

Net Income, GAAP

-60.60%

-13.41%

39.60%

Free Cash Flow

-22.37%

55.10%

58.72%

Total Cash Common Dividend

- -

Total Equity

-123.76%

-6.55%

-50.59%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

2021

136

116

102

443

2022

117

152

209

181

660

2023

162

221

216

230

829

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

2021

0.20

0.64

1.53

0.48

2.86

2022

0.44

0.16

0.45

0.43

1.48

2023

0.29

0.57

0.62

0.66

2.13

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

2021

- -

2022

- -

2023

- -

Company Description

CEO: Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.
Full Time Employees: 373
Sector: Healthcare
Industry: Biotechnology
Address: 12390 El Camino Real San Diego CA United States 92130
Website: halozyme.com
Business: Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Company News

Yahoo
3 days ago
Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?
Zacks
3 days ago
Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?
Yahoo
7 days ago
Mahesh Krishnan Elected to Halozyme's Board of Directors
Zacks
9 days ago
Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term
Yahoo
9 days ago
Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term
Zacks
10 days ago
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
Yahoo
10 days ago
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
Yahoo
10 days ago
Halozyme to Report First Quarter 2024 Financial and Operating Results
Zacks
15 days ago
Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why
Yahoo
15 days ago
Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why
Yahoo
15 days ago
Halozyme Therapeutics (HALO) Upgraded to Buy: Here's What You Should Know
Zacks
15 days ago
Halozyme Therapeutics (HALO) Upgraded to Buy: Here's What You Should Know
Tipranks
25 days ago
Analysts Offer Insights on Healthcare Companies: Ocular Therapeutix (OCUL), Marinus (MRNS) and Halozyme (HALO)
Tipranks
25 days ago
Analysts Offer Insights on Healthcare Companies: Halozyme (HALO) and MacroGenics (MGNX)
Zacks
a month ago
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
Yahoo
a month ago
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
Yahoo
a month ago
Halozyme Therapeutics (HALO) is a Top-Ranked Value Stock: Should You Buy?
Zacks
a month ago
Halozyme Therapeutics (HALO) is a Top-Ranked Value Stock: Should You Buy?
Yahoo
a month ago
Is Now The Time To Put Halozyme Therapeutics (NASDAQ:HALO) On Your Watchlist?
Zacks
a month ago
Mirum Pharmaceuticals (MIRM) Down 12.5% Since Last Earnings Report: Can It Rebound?

Company Description

CEO: Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.
Full Time Employees: 373
Sector: Healthcare
Industry: Biotechnology
Address: 12390 El Camino Real San Diego CA United States 92130
Website: halozyme.com
Business: Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Company News

Yahoo
3 days ago
Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?
Zacks
3 days ago
Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?
Yahoo
7 days ago
Mahesh Krishnan Elected to Halozyme's Board of Directors
Zacks
9 days ago
Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term
Yahoo
9 days ago
Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term
Zacks
10 days ago
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
Yahoo
10 days ago
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
Yahoo
10 days ago
Halozyme to Report First Quarter 2024 Financial and Operating Results
Zacks
15 days ago
Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why
Yahoo
15 days ago
Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why
Yahoo
15 days ago
Halozyme Therapeutics (HALO) Upgraded to Buy: Here's What You Should Know
Zacks
15 days ago
Halozyme Therapeutics (HALO) Upgraded to Buy: Here's What You Should Know
Tipranks
25 days ago
Analysts Offer Insights on Healthcare Companies: Ocular Therapeutix (OCUL), Marinus (MRNS) and Halozyme (HALO)
Tipranks
25 days ago
Analysts Offer Insights on Healthcare Companies: Halozyme (HALO) and MacroGenics (MGNX)
Zacks
a month ago
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
Yahoo
a month ago
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
Yahoo
a month ago
Halozyme Therapeutics (HALO) is a Top-Ranked Value Stock: Should You Buy?
Zacks
a month ago
Halozyme Therapeutics (HALO) is a Top-Ranked Value Stock: Should You Buy?
Yahoo
a month ago
Is Now The Time To Put Halozyme Therapeutics (NASDAQ:HALO) On Your Watchlist?
Zacks
a month ago
Mirum Pharmaceuticals (MIRM) Down 12.5% Since Last Earnings Report: Can It Rebound?